Patent intelligence · US
US 11801257
Stimulation of an immune response by enantiomers of cationic lipids
Stimulation of an immune response by enantiomers of cationic lipids
Patent details — US 11801257
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 31, 2023
- Expiration
- Oct 26, 2043
- Applicant
- PDS Biotechnology Corporation
- Claims
- 13
- CPC classes
- A61K, A61K31/685, A61P, A61P31/00
Quick answer
US 11801257 (Stimulation of an immune response by enantiomers of cationic lipids) is held by PDS Biotechnology Corporation. Status: granted. Granted Oct 31, 2023. Expires Oct 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PDS Biotechnology Corporation
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K31/685, A61P, A61P31/00, A61P31/12, A61P35/00
More from PDS Biotechnology Corporation
Related pharmaceutical patents in our USPTO index.
-
US 11911359
Stimulation of an immune response by cationic lipids
granted -
US 11911465
Vaccine compositions and methods of use
granted -
US 11904015
Vaccine compositions and methods of use
granted -
US 11638753
Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
granted -
US 11612652
Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
granted -
US 11401306
HPV16 non HLA-restricted t-cell vaccines, compositions and methods of use thereof
granted -
US 10702541
Stimulation of an immune response by enantiomers of cationic lipids
granted
Frequently asked questions
What is US patent 11801257?
US 11801257 (Stimulation of an immune response by enantiomers of cationic lipids) is held by PDS Biotechnology Corporation. Status: granted. Granted Oct 31, 2023. Expires Oct 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11801257?
PDS Biotechnology Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does US 11801257 expire?
Our index shows an expiration date of Oct 26, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.